Jefferies keeps EUR 46 target for Bayer stock: it gains 2.39 percent

Published on 10/26/2026 at 09:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FDA accepted Bayer's filing on October 8, 2026, for broader kidney use. Bayer stock costs EUR 45.03 on October 26, 2026, 2.39 percent above Xetra close.

Analyst view and clinical progress

Jefferies kept its EUR 46.00 target for Bayer on October 26, 2026.
Bayer's October 8, 2026 filing was supported by a 23 percent reduction in a kidney-cardiovascular risk measure.
Bayer stock trades at EUR 45.03 at 9:31 a.m. CET at Lang & Schwarz on October 26, 2026, 2.39 percent above the Xetra close of October 23, 2026.

Bayer, DE000BAY0017, Illustration mit AI erstellt.

Bayer stock (ISIN DE000BAY0017) trades at EUR 45.03 at Lang & Schwarz on October 26, 2026, at 9:31 a.m. CET, 2.39 percent above the Xetra close of October 23, 2026 at EUR 43.98. MarketScreener reported on October 26, 2026 that Jefferies kept its neutral view and EUR 46.00 price target. The signal is restrained, while the stock is above that target by EUR 0.97.

What is the latest analyst signal?

Jefferies analyst Michael Leuchten kept the EUR 46.00 target, according to MarketScreener on October 26, 2026. The target is 2.15 percent above the Lang & Schwarz price. That small gap makes the analyst view a measured counterweight to the day's 2.39 percent premium over the Xetra close.

Three events shape the picture

Bayer's recent chronology has three quantified markers. On October 8, 2026, Bayer said the FDA accepted its supplemental finerenone application, while the FIND-CKD study showed a 23 percent reduction in a key cardiovascular-kidney risk measure, according to Bayer. On October 24, 2026, Bayer presented interim prostate-cancer trial results showing a 58 percent lower risk of metastasis or death, as listed by MarketScreener. On October 26, 2026, Jefferies kept its EUR 46.00 target.

When are the next results?

Bayer's next disclosed reporting date is November 3, 2026. The company said its third-quarter results will be released at 7:30 a.m. CET, followed by the investor conference at 2:00 p.m. CET, according to Bayer.

Stock price and valuation context

Bayer's market capitalization is EUR 44.5 billion as of October 26, 2026. Its 52-week range is EUR 25.78 to EUR 53.92, placing the current euro quote below the upper end of that range. The next results date gives investors a defined test for the company's pharmaceutical pipeline and operating performance.

Bayer was trading at EUR 45.03 at Lang & Schwarz on October 26, 2026, at 9:31 a.m. CET, 2.39 percent above the Xetra close of October 23, 2026 at EUR 43.98. The further course of trading is shown by the continuously updated real-time quote of Bayer stock.